$PODD
INSULET CORP

2013 Q3 Form 10-Q Financial Statement

#000114519713000025 Filed on August 08, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $61.10M $60.09M $51.04M
YoY Change 11.6% 17.75% 58.44%
Cost Of Revenue $33.71M $33.26M $28.70M
YoY Change 11.02% 15.87% 62.42%
Gross Profit $27.40M $26.83M $22.33M
YoY Change 12.32% 20.16% 53.6%
Gross Profit Margin 44.83% 44.65% 43.76%
Selling, General & Admin $38.94M $27.48M $26.33M
YoY Change 48.04% 4.38% 16.39%
% of Gross Profit 142.13% 102.41% 117.9%
Research & Development $5.771M $5.174M $6.521M
YoY Change -12.01% -20.66% -4.55%
% of Gross Profit 21.07% 19.28% 29.2%
Depreciation & Amortization $3.100M $2.860M $2.660M
YoY Change 19.69% 7.52% 57.4%
% of Gross Profit 11.32% 10.66% 11.91%
Operating Expenses $44.71M $32.66M $32.85M
YoY Change 36.05% -0.59% 11.53%
Operating Profit -$17.31M -$5.822M -$10.52M
YoY Change 104.38% -44.65% -29.47%
Interest Expense $100.0K $0.00 -$3.900M
YoY Change -102.56% -100.0% -13.33%
% of Operating Profit
Other Income/Expense, Net -$3.972M -$4.579M -$3.888M
YoY Change 1.38% 17.77% -13.75%
Pretax Income -$21.29M -$10.40M -$14.41M
YoY Change 71.81% -27.81% -25.83%
Income Tax $5.000K $118.0K $69.00K
% Of Pretax Income
Net Earnings -$21.29M -$10.52M -$14.48M
YoY Change 71.46% -27.33% 79.07%
Net Earnings / Revenue -34.84% -17.5% -28.36%
Basic Earnings Per Share
Diluted Earnings Per Share -$390.8K -$195.2K -$303.3K
COMMON SHARES
Basic Shares Outstanding 54.42M shares 53.43M shares 47.77M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $153.9M $150.9M $70.10M
YoY Change 142.74% 115.26% -34.3%
Cash & Equivalents $153.9M $150.9M $70.14M
Short-Term Investments
Other Short-Term Assets $5.900M $6.600M $4.300M
YoY Change 5.36% 53.49% -10.42%
Inventory $5.395M $5.979M $16.43M
Prepaid Expenses
Receivables $34.47M $33.65M $25.59M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $199.7M $197.1M $116.5M
YoY Change 74.79% 69.26% -21.86%
LONG-TERM ASSETS
Property, Plant & Equipment $31.40M $29.33M $21.42M
YoY Change 26.05% 36.93% 33.06%
Goodwill $37.54M $37.54M $37.54M
YoY Change 0.0% 0.0% -1.39%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.721M $1.886M $2.503M
YoY Change -26.23% -24.65% -19.26%
Total Long-Term Assets $89.81M $89.02M $87.21M
YoY Change 0.76% 2.07% -2.77%
TOTAL ASSETS
Total Short-Term Assets $199.7M $197.1M $116.5M
Total Long-Term Assets $89.81M $89.02M $87.21M
Total Assets $289.5M $286.2M $203.7M
YoY Change 42.34% 40.49% -14.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.12M $11.44M $13.69M
YoY Change -6.78% -16.41% 45.61%
Accrued Expenses $30.02M $20.28M $13.54M
YoY Change 68.48% 49.8% 10.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $13.85M
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $48.29M $33.85M $43.14M
YoY Change -2.12% -21.53% 62.18%
LONG-TERM LIABILITIES
Long-Term Debt $111.1M $108.7M $99.38M
YoY Change 9.46% 9.35% -4.62%
Other Long-Term Liabilities $2.567M $2.246M $2.068M
YoY Change 24.01% 8.61% -18.07%
Total Long-Term Liabilities $113.7M $110.9M $101.5M
YoY Change 9.75% 9.33% 3919.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $48.29M $33.85M $43.14M
Total Long-Term Liabilities $113.7M $110.9M $101.5M
Total Liabilities $168.1M $147.8M $144.6M
YoY Change 9.9% 2.23% 8.46%
SHAREHOLDERS EQUITY
Retained Earnings -$524.0M -$502.7M -$458.9M
YoY Change 11.17% 9.54% 14.23%
Common Stock $55.00K $54.00K $48.00K
YoY Change 14.58% 12.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $121.4M $138.3M $59.09M
YoY Change
Total Liabilities & Shareholders Equity $289.5M $286.2M $203.7M
YoY Change 42.34% 40.49% -14.69%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$21.29M -$10.52M -$14.48M
YoY Change 71.46% -27.33% 79.07%
Depreciation, Depletion And Amortization $3.100M $2.860M $2.660M
YoY Change 19.69% 7.52% 57.4%
Cash From Operating Activities $3.700M $4.370M -$11.12M
YoY Change -207.25% -139.3% 22.47%
INVESTING ACTIVITIES
Capital Expenditures -$1.820M -$1.630M -$2.550M
YoY Change -61.19% -36.08% -4.14%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$1.820M -$1.630M -$2.550M
YoY Change -61.19% -36.08% -93.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.090M 130.0K 810.0K
YoY Change -23.78% -83.95% -98.44%
NET CHANGE
Cash From Operating Activities 3.700M 4.370M -11.12M
Cash From Investing Activities -1.820M -1.630M -2.550M
Cash From Financing Activities 1.090M 130.0K 810.0K
Net Change In Cash 2.970M 2.870M -12.86M
YoY Change -144.26% -122.32% -669.03%
FREE CASH FLOW
Cash From Operating Activities $3.700M $4.370M -$11.12M
Capital Expenditures -$1.820M -$1.630M -$2.550M
Free Cash Flow $5.520M $6.000M -$8.570M
YoY Change 345.16% -170.01% 33.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
11441000 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9361000 USD
CY2012Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
39921000 USD
CY2013Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
40434000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
4691000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6800000 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
525679000 USD
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
641016000 USD
CY2012Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2500000 USD
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3800000 USD
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33294000 USD
CY2013Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
33650000 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19051000 USD
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20276000 USD
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P9Y
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5100000 USD
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6627000 USD
CY2013Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6784000 USD
CY2013Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2751000 USD
CY2012Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2387000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
5511000 USD
CY2012Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
149000 USD
CY2013Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
149000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
297000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
297000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6133000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4988000 USD
CY2013Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1300000 USD
CY2012Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2700000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3200000 USD
CY2013Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9594181 shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9968494 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9594181 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9968494 shares
CY2012Q4 us-gaap Assets
Assets
198059000 USD
CY2013Q2 us-gaap Assets
Assets
286152000 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
109936000 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
197129000 USD
CY2013Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
1236000 USD
CY2012Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
4284000 USD
CY2012Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
0 USD
CY2013Q2 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
3048000 USD
CY2013Q2 us-gaap Capital Leases Future Minimum Payments Due
CapitalLeasesFutureMinimumPaymentsDue
5436000 USD
CY2013Q2 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
1812000 USD
CY2013Q2 us-gaap Capital Leases Future Minimum Payments Due In Three Years
CapitalLeasesFutureMinimumPaymentsDueInThreeYears
906000 USD
CY2013Q2 us-gaap Capital Leases Future Minimum Payments Due In Two Years
CapitalLeasesFutureMinimumPaymentsDueInTwoYears
1812000 USD
CY2013Q2 us-gaap Capital Leases Future Minimum Payments Remainder Of Fiscal Year
CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear
906000 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150944000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57293000 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93955000 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70144000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-23811000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
93651000 USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54329612 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48359063 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54329612 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48359063 shares
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
54000 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
48000 USD
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.29
CY2012 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.19
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
65460000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
56162000 USD
CY2012Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28704000 USD
CY2012Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
43000 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
191000 USD
CY2013Q2 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
88000 USD
us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
63000 USD
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
26523 shares
CY2013Q2 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
620122 shares
CY2013Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
33259000 USD
CY2013Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
35080000 USD
CY2012Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
40591000 USD
CY2013Q2 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
1707000 USD
CY2012Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
2004000 USD
CY2012Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
26000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
52000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
58000 USD
CY2013Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
30000 USD
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
5400000 USD
CY2013Q2 us-gaap Deferred Revenue
DeferredRevenue
900000 USD
CY2013Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
900000 USD
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5445000 USD
CY2013Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
500000 USD
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
500000 USD
CY2013Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
700000 USD
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
700000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5498000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5763000 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.20
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2013Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
30100000 USD
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
4300000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2431000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4249000 USD
CY2013Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
12633000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9937000 USD
CY2013Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
32900000 USD
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
22963000 USD
CY2013Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20267000 USD
CY2011Q2 us-gaap Finitelived Intangible Assets Acquired1
FinitelivedIntangibleAssetsAcquired1
32900000 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12665000 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13901000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25685000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
26995000 USD
CY2013Q2 us-gaap Goodwill
Goodwill
37536000 USD
CY2012Q4 us-gaap Goodwill
Goodwill
37536000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2013Q2 us-gaap Gross Profit
GrossProfit
26833000 USD
CY2012Q2 us-gaap Gross Profit
GrossProfit
22331000 USD
us-gaap Gross Profit
GrossProfit
51988000 USD
us-gaap Gross Profit
GrossProfit
42627000 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2695000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-20935000 USD
CY2012Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14407000 USD
CY2012Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
69000 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
118000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
249000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
115000 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10401000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-29141000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3887000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2924000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1434000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4545000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4588000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-8888000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
379000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
16000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2055000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
725000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
8971000 USD
CY2013Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
4616000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
7779000 USD
CY2012Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
3912000 USD
CY2013Q2 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
9142000 USD
CY2013Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4685000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
8086000 USD
CY2012Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4085000 USD
CY2012Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
11785000 USD
CY2013Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
4192000 USD
CY2013Q2 us-gaap Inventory Net
InventoryNet
5979000 USD
CY2012Q4 us-gaap Inventory Net
InventoryNet
14867000 USD
CY2013Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
1422000 USD
CY2012Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1487000 USD
CY2012Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1595000 USD
CY2013Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
365000 USD
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
24000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
52000 USD
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
64000 USD
CY2013Q2 us-gaap Liabilities
Liabilities
147817000 USD
CY2012Q4 us-gaap Liabilities
Liabilities
153883000 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
198059000 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
286152000 USD
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
48286000 USD
CY2013Q2 us-gaap Liabilities Current
LiabilitiesCurrent
33853000 USD
CY2012Q4 us-gaap Long Term Debt
LongTermDebt
118159000 USD
CY2013Q2 us-gaap Long Term Debt
LongTermDebt
108670000 USD
CY2013Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2012Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
14429000 USD
CY2012Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
103730000 USD
CY2013Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
108670000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of the Business</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is primarily engaged in the development, manufacturing and sale of its proprietary OmniPod Insulin Management System (the &#8220;OmniPod System&#8221;), an innovative, discreet and easy-to-use insulin infusion system for people with insulin-dependent diabetes. The OmniPod System is the only commercially-available insulin infusion system of its kind. The OmniPod System features a unique disposable tubeless OmniPod which is worn on the body for approximately three days at a time and the handheld, wireless Personal Diabetes Manager (&#8220;PDM&#8221;). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear a number of cumbersome components, including up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">42</font><font style="font-family:inherit;font-size:10pt;"> inches of tubing. In contrast, the OmniPod System features two discreet, easy-to-use devices that eliminate the need for a bulky pump, tubing and separate blood glucose meter, provides for virtually pain-free automated cannula insertion, communicates wirelessly and integrates a blood glucose meter. </font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2011, the Company acquired Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, &#8220;Neighborhood Diabetes&#8221;) in order to support the sales of the OmniPod System, expand the Company&#8217;s full suite diabetes management product offerings and obtain access to a larger number of insulin dependent patients. Through Neighborhood Diabetes, the Company is able to provide customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals and has the ability to process claims as either durable medical equipment or through pharmacy benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company began commercial sale of the OmniPod System in the United States in October 2005. The Company has also expanded the availability of the OmniPod System internationally through its partnership with Ypsomed Distribution AG (&#8220;Ypsomed&#8221;) and GlaxoSmithKline (&#8220;GSK&#8221;). In January 2010, the Company entered into a distribution agreement with Ypsomed pursuant to which Ypsomed became the exclusive distributor of the OmniPod System in multiple countries. In February 2011, the Company entered into a distribution agreement with GSK pursuant to which GSK became the exclusive distributor of the OmniPod System in Canada. </font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2011, the Company received CE Mark approval, and in December 2012 the Company received 510(k) clearance by the FDA for its new OmniPod System. The new OmniPod System is more than one-third smaller and one-quarter lighter than the original model, while maintaining the same features and operating capabilities. The Company began selling the new OmniPod System in certain countries in Europe through Ypsomed in 2012. The Company began selling the new OmniPod System to new customers in the U.S. during the first quarter of 2013 and began converting the existing customer base in the second quarter of 2013.</font></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
93174000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
455000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2695000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4249000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
3172000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20017000 USD
us-gaap Net Income Loss
NetIncomeLoss
-21184000 USD
us-gaap Net Income Loss
NetIncomeLoss
-29256000 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-14476000 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-10519000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
32850000 USD
us-gaap Operating Expenses
OperatingExpenses
64016000 USD
us-gaap Operating Expenses
OperatingExpenses
64041000 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
32655000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-21414000 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5822000 USD
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10519000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12028000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1781000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1046000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
45000 USD
CY2013Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
690000 USD
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2202000 USD
CY2013Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1886000 USD
CY2013Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2246000 USD
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1867000 USD
CY2012Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3888000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7727000 USD
CY2013Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4579000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8907000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1187000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6568000 USD
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4482000 USD
CY2013Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6556000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
97605000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1642000 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
97800000 USD
CY2012Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2033000 USD
CY2012Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1992000 USD
CY2012Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1822000 USD
CY2013Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2401000 USD
CY2013Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
2249000 USD
CY2011Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
1960000 USD
CY2012Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
863000 USD
CY2013Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
934000 USD
CY2013Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1467000 USD
CY2012Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
1129000 USD
CY2012Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
559000 USD
CY2013Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
633000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1252000 USD
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
1360000 USD
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1222000 USD
CY2012Q2 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
348000 USD
us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
1661000 USD
CY2013Q2 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
785000 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
29334000 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25422000 USD
us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P5Y
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2568000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1486000 USD
us-gaap Repayments Of Debt
RepaymentsOfDebt
2000000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
47838 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
240400 shares
podd Renewal Option Terms Additional Period
RenewalOptionTermsAdditionalPeriod
P5Y
podd Return Period
ReturnPeriod
P45D
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-481551000 USD
us-gaap Repayments Of Debt
RepaymentsOfDebt
0 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5174000 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6521000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9570000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11953000 USD
CY2013Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-502735000 USD
CY2013Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
20.75
CY2013Q2 us-gaap Sales Revenue Net
SalesRevenueNet
60092000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
98789000 USD
CY2012Q2 us-gaap Sales Revenue Net
SalesRevenueNet
51035000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
117448000 USD
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1385193 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.91
CY2013Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13580000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
27451000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
26403000 USD
CY2012Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
13664000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
5155000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
6844000 USD
CY2007Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
535000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37410000 USD
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2283054 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2502190 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.51
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.02
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
33474000 USD
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1957919 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
10.85
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.55
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.55
CY2013Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
27006000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M15D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M50D
CY2012Q1 podd Maximum Annualauthorized Share Increaes
MaximumAnnualauthorizedShareIncreaes
725000 shares
us-gaap Stock Issued1
StockIssued1
13000000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4715000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
411698 shares
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
138335000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
44176000 USD
CY2013Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
CY2012Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
100000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates in Preparation of Financial Statements</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expense during the reporting periods. The most significant estimates used in these financial statements include the valuation of stock-based compensation expense, accounts receivable, inventories, goodwill, deferred revenue and equity instruments, the lives of property and equipment and intangible assets, as well as warranty and doubtful accounts allowance reserve calculations. Actual results may differ from those estimates.</font></div></div>
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47824190 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53445715 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
47715819 shares
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53834707 shares
podd Capital Lease Effective Interest Rate
CapitalLeaseEffectiveInterestRate
0.17
podd Capital Lease Term
CapitalLeaseTerm
P36M
podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
3009000 USD
CY2012Q2 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1549000 USD
CY2013Q2 podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
1460000 USD
podd Debt Instrument Stated Coupon Rate Interest Expense
DebtInstrumentStatedCouponRateInterestExpense
3098000 USD
CY2012Q2 podd Dollarequivalentofsharesissuedatconversation
Dollarequivalentofsharesissuedatconversation
0 USD
CY2013Q2 podd Dollarequivalentofsharesissuedatconversation
Dollarequivalentofsharesissuedatconversation
325000 USD
podd Dollarequivalentofsharesissuedatconversation
Dollarequivalentofsharesissuedatconversation
325000 USD
podd Dollarequivalentofsharesissuedatconversation
Dollarequivalentofsharesissuedatconversation
0 USD
CY2013 podd Expected Decrease In Uncertain Tax Positions
ExpectedDecreaseInUncertainTaxPositions
100000 USD
podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
3305000 USD
podd Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
2730000 USD
CY2012Q4 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
2 customer
CY2013Q2 podd Number Of Customers With Greater Than Ten Percent Accounts Receivable Balance
NumberOfCustomersWithGreaterThanTenPercentAccountsReceivableBalance
1 customer
CY2013Q2 podd Number Of Financial Institution
NumberOfFinancialInstitution
2 location
CY2013Q2 podd Number Of Inches Of Tubing In Conventional Insulin Pump
NumberOfInchesOfTubingInConventionalInsulinPump
42 in
CY2013Q2 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2012Q4 podd Number Of Single Source Suppliers
NumberOfSingleSourceSuppliers
1 customer
CY2013Q1 podd Proceeds Of Issuance Of Common Stock Net Of Expenses
ProceedsOfIssuanceOfCommonStockNetOfExpenses
92800000 USD
podd Product Warranty Term
ProductWarrantyTerm
P4Y
CY2013Q2 podd Product Warranty Term
ProductWarrantyTerm
P4Y
podd Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitures
0.16
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001145197
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54418963 shares
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
INSULET CORP
dei Trading Symbol
TradingSymbol
PODD

Files In Submission

Name View Source Status
0001145197-13-000025-index-headers.html Edgar Link pending
0001145197-13-000025-index.html Edgar Link pending
0001145197-13-000025.txt Edgar Link pending
0001145197-13-000025-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
podd-20130630.xml Edgar Link completed
podd-20130630.xsd Edgar Link pending
podd-20130630_cal.xml Edgar Link unprocessable
podd-20130630_def.xml Edgar Link unprocessable
podd-20130630_lab.xml Edgar Link unprocessable
podd-20130630_pre.xml Edgar Link unprocessable
podd-2013x06x30x10xq.htm Edgar Link pending
podd-ex101_2013630xq2.htm Edgar Link pending
podd-ex311_2013630xq2.htm Edgar Link pending
podd-ex312_2013630xq2.htm Edgar Link pending
podd-ex321_2013630xq2.htm Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R26.htm Edgar Link pending
R26.xml Edgar Link unprocessable
R27.htm Edgar Link pending
R27.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R28.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R29.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R30.xml Edgar Link unprocessable
R31.htm Edgar Link pending
R31.xml Edgar Link unprocessable
R32.htm Edgar Link pending
R32.xml Edgar Link unprocessable
R33.htm Edgar Link pending
R33.xml Edgar Link unprocessable
R34.htm Edgar Link pending
R34.xml Edgar Link unprocessable
R35.htm Edgar Link pending
R35.xml Edgar Link unprocessable
R36.htm Edgar Link pending
R36.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R37.xml Edgar Link unprocessable
R38.htm Edgar Link pending
R38.xml Edgar Link unprocessable
R39.htm Edgar Link pending
R39.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R40.htm Edgar Link pending
R40.xml Edgar Link unprocessable
R41.htm Edgar Link pending
R41.xml Edgar Link unprocessable
R42.htm Edgar Link pending
R42.xml Edgar Link unprocessable
R43.htm Edgar Link pending
R43.xml Edgar Link unprocessable
R44.htm Edgar Link pending
R44.xml Edgar Link unprocessable
R45.htm Edgar Link pending
R45.xml Edgar Link unprocessable
R46.htm Edgar Link pending
R46.xml Edgar Link unprocessable
R47.htm Edgar Link pending
R47.xml Edgar Link unprocessable
R48.htm Edgar Link pending
R48.xml Edgar Link unprocessable
R49.htm Edgar Link pending
R49.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R50.htm Edgar Link pending
R50.xml Edgar Link unprocessable
R51.htm Edgar Link pending
R51.xml Edgar Link unprocessable
R52.htm Edgar Link pending
R52.xml Edgar Link unprocessable
R53.htm Edgar Link pending
R53.xml Edgar Link unprocessable
R54.htm Edgar Link pending
R54.xml Edgar Link unprocessable
R55.htm Edgar Link pending
R55.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending